Abstract. Adhesion regulating molecule 1 (ADRM1), a 19S proteasome cap-associated protein, and nuclear factor kappa B (NF-κB), a protein transcription factor controlling DNA transcription, may play an important role in tumorigenesis. Overexpression of ADRM1 and activation of NF-κB are wellobserved in hepatocellular carcinoma (HCC). However, little is known about whether both are functionally connected during hepatocarcinogenesis, and the mechanisms involved. In this study, using laboratory techniques including short hairpin RNA (shRNA)-mediated knockdown, immunohistochemistry (IHC), both semi-quantitative and real-time RT-PCR, western blotting, MTT assay, transwell assay, flow cytometry and electrophoretic mobility shift assay (EMSA), the expression of ADRM1, the effects of ADRM1 knockdown on NF-κB activity, as well as the biological behavior of HCC cells including proliferation, migration, invasion and apoptosis were investigated in the samples from HCC patients and HCC cell lines. We found that both mRNA and protein levels of ADRM1 were increased in HCC tissues and that this increase in ADRM1 expression was parallel to the metastatic potential of HCC cell lines. After ADRM1 knockdown in MHCC97-H cells, the expression of IκB-α was increased and the NF-κB activity was reduced. Furthermore, ADRM1 knockdown inhibited MHCC97-H cell proliferation and induced cell apoptosis, and the migration and invasion of MHCC97-H cells were significantly repressed. These results indicate that there is a clear functional connection between ADRM1 and NF-κB in hepatocarcinogenesis, despite the precise mechanisms through which the two work together still being unknown.
Introduction
Adhesion-regulating molecule 1 (ADRM1), a 19S proteasome cap-associated protein that recruits the deubiquitinating enzyme UCH37 to the 26S proteasome (1) (2) (3) (4) , has been recognized as a novel ubiquitin receptor (5) . ADRM1 is widely involved in cell biological processes such as differentiation, migration, and adhesion (6) (7) (8) . It is crucial for spermatogenesis and oogenesis in mammals (9) . Accumulating evidence has suggested that ADRM1 may hold an important role in tumorigenesis as well. Studies show that ADRM1 is commonly overexpressed in tumors of different sources including liver, lung, colon, bladder, kidney, stomach and ovary (10, 11) . ADRM1 is also identified as an amplification target in ovarian cancer, and its overexpression is significantly associated with earlier recurrence and worse survival (12) .
Nuclear factor kappa B (NF-κB), which is a protein transcription factor controlling DNA transcription, plays a key role in immune response and is involved in tumorigenesis of many types of cancer (13) (14) (15) . In quiescent cells, NF-κB normally stays in an inactive form in the cytoplasm by interacting with inhibitors of κB (IκBs) that mask its nuclear localization sequence (16) . Under some pathological conditions, such as cancer, aberrant constitutive NF-κB activation occurs. This abnormality is mainly attributed to malfunction of IκB-α (15) . Persistent NF-κB activation has been observed in hepatocellular carcinoma (HCC) (16) (17) (18) . It has been regarded as an important step in hepatocarcinogenesis (19, 20) . However, whether ADRM1 has any functional connections with NF-κB/IκB as regards hepatocarcinogenesis is still poorly known.
In this study, using the samples from HCC patients and HCC cell lines, the expressions of ADRM1, the effects of ADRM1 knockdown on NF-κB activity, as well as the biological behavior of HCC cells, including proliferation, migration, invasion and apoptosis, were investigated collectively, which would help obtain further insight into the role of ADRM1 and NF-κB/IκB in the pathogenesis of HCC. Data were calculated with the 2 -∆∆Ct method, which is a conve- Table I . Relationship between ADRM1 expression and clinicopathological parameters in HCC tissues. nient way to analyze the relative changes in gene expression from real-time RT-PCR (21, 22) , and expressed as relative expression (RQ value) of transcripts normalized to GAPDH.
Materials and methods

Human
Immunohistochemistry. Immunohistochemistry (IHC) was performed on deparaffinized and rehydrated formalin-fixed paraffin sections to determine the protein expression of ADRM1 in 68 cases of HCC tissues and adjacent non-tumor liver tissues. Antigen retrieval was carried out by immersing the sections in the citrate buffer (pH 6.0) and heating them at 100˚C in a microwave oven for 6x2 min. Endogenous peroxidase activity was blocked by incubating the sections in methanol containing 0.3% hydrogen peroxide for 10 min. After pretreatment with 10% normal goat serum, the slides were incubated with primary antibody against ADRM1 (1:100 dilution; Proteintech Group, Chicago, IL, USA) at 4˚C overnight, and subsequently, with HRP-conjugated secondary antibody at room temperature for 1 h. Sections were then stained with 3,3'-diaminobenizidine, counterstained with hematoxylin, dehydrated, and mounted in Permount. As a negative control, PBS was used instead of the primary antibody. Immunoreactivity was evaluated independently by two observers, who were blinded to the patients' clinicopathologic data. The staining intensities were scored as: none, weak, moderate, and strong, as previously described (12) . Discrepancies were rechecked and final decisions were reached by consensus. For statistical analysis, ADRM1 expression was classified into two groups: low expression was defined as none or weak staining, and high expression was defined as moderate or strong staining.
Western blot analysis. Cells were harvested, washed with cold PBS and then lysed by incubating with the cell lysis buffer (Beyotime, China) for 30 min on ice. Cell lysates were cleared by centrifugation and supernatant was collected. Nuclear protein extracts were prepared with the NucBuster™ Protein Exaction kit (Merck Biosciences, Germany) according to the manufacturer's protocols. Protein concentration was determined by using a BCA kit (Beyotime, China). To evaluate the protein expression of ADRM1, IκB-α and nuclear NF-κB p65 in HCC cells, Western blot assays were performed. Equal amounts of proteins that were obtained from whole cell lysis or nuclear extracts were resolved by 10% SDS-PAGE, and transferred to PVDF membranes (Pierce Biotechnology, USA). The membranes were blocked with 5% non-fat dry milk in PBS (37˚C for 2 h), and incubated with primary antibodies as follows: rabbit polyclonal ADRM1 antibody (1:300 dilution; Proteintech Group), rabbit polyclonal IκB-α antibody (1:500 dilution; Santa Cruz Biotechnology, Santa Cruz, USA), rabbit polyclonal NF-κB p65 antibody (1:500 dilution; Cell Signaling Technology, Beverly, MA, USA), rabbit monoclonal GAPDH antibody (1:1000 dilution; Cell Signaling Technology, Danvers, MA, USA) and rabbit polyclonal histone H2A.X antibody (1:400 dilution, Cell Signaling Technology, Beverly, MA, USA) at 4˚C overnight. After washing, the membranes were incubated with HRP-conjugated secondary antibodies (goat anti-rabbit IgG, 1:5000 dilution; Santa Cruz Biotechnology) and the immunolabeled proteins were detected by enhanced chemiluminescence (ECL). The film was scanned, and the image was analyzed with Gel-Pro 4.0. The relative levels of target protein were represented as the ratio of target protein-IOD and GAPDH-IOD (for ADRM1 and IκB-α from whole cell lysis) or histone H2A.X-IOD (for NF-κB p65 from nuclear extracts). MTT assay. Cell proliferation was assessed by MTT assay. In brief, cells were harvested and seeded in a 96-well plate (1x10 4 cells per well), then, transfected with shRNA expression plasmids and were allowed to grow for 24, 48 and 72 h at 37˚C with 5% CO 2 . MTT (Keygen, China) and DMSO were then added, and the absorbance at 570 nm was measured with a model 680 microtiter plate reader (Bio-Rad, USA). The MTT assays were performed in triplicate. Cell growth curves were calculated as mean values for each group.
Construction of short hairpin
Apoptosis analysis by flow cytometry. Cell apoptosis was assessed by flow cytometry using an annexin V-FITC/propidium iodide (PI) apoptosis detection kit (Keygen, China). Briefly, cells were trypsinized, washed, re-suspended in a binding buffer at a concentration of 1x10 6 cells/ml, and then stained with annexin-V and PI. After incubation for 15 min at room temperature in the dark, cells were analyzed by flow cytometry with FACS Aria (BD Biosciences, USA). Assays were replicated three times. Cells that were annexin-V-positive and PI-negative were considered as early apoptotic while annexin V-positive and PI-positive ones were classified as late apoptotic cells (23) .
In vitro invasion and migration assays. Invasion assays were performed using transwell chambers (Corning, USA, pore size 8 µm) coated with matrigel (BD Biotechnology, USA). Forty-eight hours after transfection, the cells were suspended in serum-free medium containing 5% BSA at a density of 5x10 4 /ml. Then the cell suspension (2 ml) was added into the upper compartment of the transwell, and the lower chamber was filled with 10% FBS medium. After 24 h of incubation, cells were fixed with 95% ethanol and stained with hematoxylin-eosin. Invading cells were counted from five randomly selected fields (at magnification x250). Migration assays were conducted as described above but without matrigel. Three independent experiments were done for each assay.
Electrophoretic mobility shift assay (EMSA).
To detect the DNA-binding activity of NF-κB, EMSA was performed with a LightShift Chemiluminescent EMSA kit (Pierce). A doublestranded NF-κB probe (sense sequence: 5'-AGTTGAGGGGACT TTCCCAGGC-3') was purchased from Beyotime Biotechnology (Haimen, China). The biotin-labeled probe (0.5 µl) was incubated with 10 µg nuclear protein extracts in a binding buffer. The reaction mixture was separated on a 0.5X TBE polyacrylamide gel, transferred to a nylon membrane (Amersham Biosciences, Sweden), and then UV cross-linked. Signals were detected by streptavidin-HRP conjugate. Labeled probe without protein was used as a negative control, and HeLa cell nuclear extracts served as a positive control.
Statistical analysis. Statistical analysis was performed with SPSS version 13.0 (SPSS Inc., Chicago, IL, USA). Data were expressed as mean ± SD. The correlation between ADRM1 expression and clinicopathological variable was analyzed by χ 2 test. Differences between two groups were evaluated by t-test. Differences between multiple groups were assessed by one-way ANOVA test. P<0.05 was considered statistically significant.
Results
ADRM1 expression was up-regulated in HCC.
Compared to matched non-tumor liver tissues, ADRM1 mRNA expression levels in HCC tissues were significantly elevated (Fig. 1A,  P<0 .05). To further investigate the properties of ADRM1 expression in HCC, we performed IHC analysis on a series of 68 HCC tissues and adjacent non-tumor liver tissues. Positive labeling for ADRM1 was localized mainly in the nucleus, and partially in the surrounding cytoplasm (Fig. 1B) . The high expression of ADRM1 was more frequently detected in HCC tissues (33/68, 49%) than in adjacent non-tumor liver tissues (6/68, 9%). Positive correlations between ADRM1 expression and venous invasion was also observed (Table I, P=0.002).
ADRM1 expression was up-regulated corresponding to the metastatic potential of HCC cell lines. RT-PCR and Western
blot analyses were performed for detecting the expression levels of ADRM1 in Hep3B, MHCC97-L and MHCC97-H cells, which have non-, high and higher metastatic capacities, respectively (24) . Results showed that both ADRM1 mRNA and protein levels increased stepwise in accordance with their metastatic potential ( Fig. 2A and B) . To test whether suppressing ADRM1 in HCC cells could reduce their oncogenic potential, shRNAmediated ADRM1 knockdown was performed in MHCC97-H cells that expressed the highest level of ADRM1. Real-time RT-PCR analysis showed that all three of the ADRM1 shRNA plasmids (namely, pGPU6/GFP/Neo-ADRM1-204, pGPU6/ GFP/Neo-ADRM1-351 and pGPU6/GFP/Neo-ADRM1-1046) down-regulated ADRM1 mRNA, while the plasmid pGPU6/ GFP/Neo-ADRM1-351 caused the greatest reduction of ADRM1 mRNA level (Fig. 2C) . Western blot analysis consistently demonstrated that this plasmid significantly suppressed ADRM1 protein expression (Fig. 2D) . Thereby, the plasmid pGPU6/GFP/ Neo-ADRM1-351 was selected for subsequent experiments.
Knockdown of ADRM1 suppressed proliferation, invasion and migration of MHCC97-H cells and induced cell apoptosis.
At 48 and 72 h after transfection, the ADRM1 shRNA-transfected cells had a significantly reduced proliferation level compared with the untransfected cells (Fig. 3, P<0 .05). The number of migrated cells decreased significantly in the ADRM1 shRNAtransfected cells (Fig. 4A, P<0 .05). ADRM1 knockdown also significantly reduced the number of invading cells (Fig. 4B,  P<0 .05). No significant differences between the untransfected and shNC-transfected cells were observed.
The percentage of early apoptotic cells and late apoptotic ones was significantly increased in the ADRM1 knockdown group (Fig. 5, P<0 .05). Again, no significant difference was observed between the untransfected and shNC-transfected cells.
ADRM1 was responsible for increased NF-κB activity in HCC cells.
To explore the relationship between ADRM1 and NF-κB, we first analyzed protein levels of nuclear NF-κB p65 and IκB-α in Hep3B, MHCC97-L and MHCC97-H cells. Western blot analysis revealed that nuclear p65 expression increased in these 3 cell lines, following the pattern of their ADRM1 levels, with Hep3B having the lowest, and MHCC97-H the highest nuclear p65 levels. In contrast, IκB-α expression showed an opposite tendency (Fig. 6A) . ADRM1 knockdown by ADRM1 shRNA transfection of MHCC97-H cells inhibited nuclear p65 expression; on the contrary, IκB-α expression was elevated (Fig. 6B) . Furthermore, EMSA assay showed that the DNA-binding activity of NF-κB in MHCC97-H cells was reduced by ADRM1 knockdown (Fig. 6C ).
Discussion
Although ADRM1 may be tumorigenic, more details regarding its roles in the cell biology of HCC are still required. In this study, we confirmed that both mRNA and protein levels of ADRM1 were significantly higher in HCC tissues than in non-tumor liver tissues. That is in line with another report (10) . A positive correlation between ADRM1 expression in HCC tissues and venous invasion of HCC, which was checked by clinical pathology, was also found in this study. Similar results were found in vitro, in which ADRM1 expression was increased in parallel with the metastatic potential of HCC cell lines. Furthermore, by knockdown of ADRM1 using RNA interference technology, we found that suppression of ADRM1 expression inhibited MHCC97-H cell proliferation and induced cell apoptosis, and the migration and invasion of MHCC97-H cells were significantly repressed. These findings imply that overexpression of ADRM1 may represent a metastatic character, and plays an oncogenic role in the progression of HCC. Likewise, ADRM1 overexpression has been found significantly related to metastasis of breast carcinoma cells (6), ovarian cancer (12) and colorectal cancer (25) . Our findings serve as one more piece of supporting evidence for this hypothesis.
As a proteasome-associated protein and a ubiquitin receptor, ADRM1 may be secreted (7, 26) . It may act through influencing a certain signaling pathway, such as NF-κB (27) , which mediates tumor cells growth, invasion and migration, considering that a persistent NF-κB activation has been widely observed in HCC (16) (17) (18) . In this study, ADRM1 knockdown in MHCC97-H cells increased the expression of IκB-α and attenuated the nuclear translocation of NF-κB p65. Most importantly, the NF-κB activity in MHCC97-H cells was reduced in response to ADRM1 knockdown. A functional connection between ADRM1 and NF-κB in hepatocarcinogenesis is clearly revealed, though the exact mechanisms are still not known. As IκB-α functions as a key regulator of NF-κB and degradation of IκB-α is critically regulated by the 26S proteasome degradation pathway (14) , a reasonable explanation for our results is that ADRM1 overexpression in HCC cells enhances IκB-α degradation, resulting in more nuclear translocation of NF-κB p65 and consequently increasing NF-κB activity.
In conclusion, the overexpression of ADRM1 in HCC was detected in this study, and it is highly involved in tumorigenic processes of HCC such as proliferation, migration, invasion and apoptosis. A clear connection between ADRM1 and NF-κB in hepatocarcinogenesis was also revealed; an activated NF-κB activity in HCC might be the results of enhanced degradation of IκB-α by ADRM1, even though more work is needed to understand the precise mechanisms. 
